Drug Trial Radar · NCT03927144
Study of Sustained Benefit of AMG334 in Adult Episodic Migraine Patients
Last checked: Nov 20, 2026Latest source record: Nov 18, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
621
Actual
Start
May 15, 2019
Primary completion
Oct 1, 2021
Study completion Sep 30, 2022
Sponsor
- Lead sponsor
- AmgenAmgen (AMGN)
- Sponsor type
- Industry
- Collaborators
- Novartis
- First posted
- Apr 25, 2019
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to compare the sustained long-term benefit between two treatment paradigms of migraine prophylactic agents (erenumab versus a control arm of oral prophylactics) in episodic migraine patients who have previously failed 1 to 2 prophylactic migraine treatments.
Conditions
- Episodic Migraine
Interventions
AMG334Drug
Subcutaneous Injection
Oral ProphylacticDrug
SOC Oral Tablet/Capsule
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants Who Completed Initially Assigned Treatment and Achieved at Least a 50% Reduction From Baseline in Monthly Migraine Days at Month 12Time frame: Baseline and Month 12
Locations
112 sites in 18 countries. Site status is shown where the registry gives one.
Stanford Headache Center
Stanford, California
Yale Center for Clinical Research
New Haven, Connecticut
New England Institute for Neurology and Headache
Stamford, Connecticut
George Washington Hospital
Washington D.C., District of Columbia
University of Miami Headache Division
Miami, Florida
Premier Research Institute
West Palm Beach, Florida
Diamond Headache Clinic
Chicago, Illinois
Robbins Headache Clinic
Riverwoods, Illinois
Medvadis
Watertown, Massachusetts
New England Regional Headache Center, Inc
Worcester, Massachusetts
MHNI
Ann Arbor, Michigan
Clinical Research Institute
Minneapolis, Minnesota
The Headache Center
Ridgeland, Mississippi
Study Metrix Research
City of Saint Peters, Missouri
Mercy Health Research
St Louis, Missouri
Laszlo Mechtler
Amherst, New York
Jefferson Headache Center
Philadelphia, Pennsylvania
Nashville Neuroscience Group
Nashville, Tennessee
Texas Neurology
Dallas, Texas
Texas Institute for Neurological Disorders
Sherman, Texas
IDIM Instituto de Investigaciones Metabolicas
Buenos Aires, Argentina
Mautalen Salud e Investigacion
Ciudad Autonoma de Bs As, Argentina
Centro Medico Privado en Reumatologia
San Miguel de Tucumán, Argentina
Univ. Klinik fuer Neurologie
Innsbruck, Austria
Ordensklinikum Linz Barmherzigen Schwestern
Linz, Austria
Univ Klinik fuer AKH
Vienna, Austria
AZ Sint Jan
Bruges, Belgium
UZ Brussel
Brussels, Belgium
UZ Gent
Ghent, Belgium
Jessa Ziekenhuis- Campus Virga Jesse Dienst Gastro-entrologie
Hasselt, Belgium
Centre Hospitalier Regional de la Citadelle
Liège, Belgium
Heilig Hart Ziekenhuis Lier
Lier, Belgium
Neurologicka ambulance Quattromedica
Brno, Czechia
NEUROHK sro
Choceň, Czechia
Brain Soultherapy sro
Kladno, Czechia
DADO Medical S R O
Prague, Czechia
Thomayerova Nemocnice
Prague, Czechia
Forbeli SRO
Prague, Czechia
Institut neuropsychiatricke pece
Prague, Czechia
Clintrial SRO
Prague, Czechia
Showing 40 of 112 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.